Drug Trial Radar · NCT06356129
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
850
Planned (sponsor's estimate)
Start
Jun 19, 2024
Primary completion
Aug 9, 2027
Study completion Jun 26, 2029
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Conditions
- Large B-cell Lymphoma
Interventions
GolcadomideDrug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
RituximabDrug
Specified dose on specified days
CyclophosphamideDrug
Specified dose on specified days
DoxorubicinDrug
Specified dose on specified days
VincristineDrug
Specified dose on specified days
PrednisoneDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by the InvestigatorTime frame: Approximately 24 months after the last participant's first treatment
Locations
325 sites in 38 countries. Site status is shown where the registry gives one.
Local Institution - 0014
Mobile, Alabama
Local Institution - 0477
Anchorage, Alaska
Local Institution - 0452
Phoenix, Arizona
Local Institution - 0342
San Francisco, California
Local Institution - 0497
Fort Myers, Florida
Local Institution - 0287
Jacksonville, Florida
Local Institution - 0415
Margate, Florida
Local Institution - 0045
Miami Beach, Florida
Local Institution - 0012
Pensacola, Florida
Local Institution - 0502
St. Petersburg, Florida
Local Institution - 0414
Tampa, Florida
Local Institution - 0192
West Palm Beach, Florida
Local Institution - 0485
Weston, Florida
Local Institution - 0515
Atlanta, Georgia
Local Institution - 0303
Atlanta, Georgia
Local Institution - 0182
Chicago, Illinois
Local Institution - 0048
Skokie, Illinois
Local Institution - 0461
Waukee, Iowa
Local Institution - 0031
Westwood, Kansas
Local Institution - 0436
Edgewood, Kentucky
Local Institution - 0408
Baton Rouge, Louisiana
Local Institution - 0478
Ann Arbor, Michigan
Local Institution - 0067
Minneapolis, Minnesota
Local Institution - 0203
Rochester, Minnesota
Local Institution - 0437
Kansas City, Missouri
Local Institution - 0466
Reno, Nevada
Local Institution - 0498
East Brunswick, New Jersey
Local Institution - 0480
Hackensack, New Jersey
Local Institution - 0049
Morristown, New Jersey
Local Institution - 0175
New Brunswick, New Jersey
Local Institution - 0190
Buffalo, New York
Local Institution - 0451
East Syracuse, New York
Local Institution - 0484
New York, New York
Local Institution - 0369
New York, New York
Local Institution - 0176
New York, New York
Local Institution - 0174
Chapel Hill, North Carolina
Local Institution - 0066
Massillon, Ohio
Local Institution - 0450
Tulsa, Oklahoma
Local Institution - 0179
Portland, Oregon
Local Institution - 0009
Pittsburgh, Pennsylvania
Showing 40 of 325 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.